CM
BTTX

Crestline Management’s Better Therapeutics, Inc. Common Stock BTTX Stock Holding History

Crestline Management’s Portfolio BTTX Stock Details BTTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-25,300
Closed -$252K – 283
2021
Q3 		$252K Hold
25,300
– – 0.02% 193
2021
Q2 		$251K Buy
+25,300
New +$251K 0.02% 150

Other funds holding BTTX

FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
SAM
Sectoral Asset Management Montreal, Quebec, Canada $143M AUM 102.52% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return
MIM
Monashee Investment Management Boston, Massachusetts $59.6M AUM 181.61% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
BWLSA
Blue Water Life Science Advisors Larkspur, California $159M AUM 139.66% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Crestline Management's BTTX Position: Q4 2021 in Review

Crestline Management sold out of Better Therapeutics, Inc. Common Stock (BTTX) in Q4 2021, closing a stake of 25,300 shares — an estimated $252K sold.

Crestline Management first reported a position in BTTX in Q2 2021 and held it in 2 quarters. The position peaked at $252K in Q3 2021. 20 funds tracked by Wall St. Rank hold BTTX as of Q4 2021.

  • Crestline Management reported no remaining Better Therapeutics, Inc. Common Stock position as of Q4 2021 after selling out during the quarter.
  • Crestline Management sold 25,300 Better Therapeutics, Inc. Common Stock shares in Q4 2021, an estimated $252K.
  • Crestline Management first reported a position in Better Therapeutics, Inc. Common Stock in Q2 2021 and held it in 2 quarters.
  • Crestline Management's Better Therapeutics, Inc. Common Stock position peaked at $252K in Q3 2021.
  • 20 funds tracked by Wall St. Rank held Better Therapeutics, Inc. Common Stock as of Q4 2021.

Based on Crestline Management's 13F filing for Q4 2021, filed 14 Feb 2022.